Lv43
790 积分 2025-08-21 加入
Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development
1天前
已完结
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
7天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
27天前
已完结
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
1个月前
已完结
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Are ultrasensitive ctDNA assays ready for clinical use in early-stage NSCLC?
1个月前
已完结
OA13.02 Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
1个月前
已关闭
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
2个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
